maintenance hemodialysis
Conditions
Interventions
Treatment group:On the basis of routine treatment of maintenance hemodialysis patients, oral Bailing capsules (0.5g/ tablets) are taken 3 times a day, 4 tablets each time for 6 months.
Control group:Routine treatment for maintenance hemodialysis patients without special intervention.
Sponsors
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: i. Age = 18 years old, regardless of sex ii. Maintenance hemodialysis patients (regular dialysis = 3 months), 3 times per week, 4h/ times iii.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: i. Allergic to Bailing capsule or Cordyceps sinensis ii. Patients who have taken Bailing capsule or other Cordyceps sinensis medicine within 3 months iii. Patients who were treated with immunosuppressive drugs (including glucocorticoids) within 1 month iv. Patients who receive immuno enhancer therapy within 1 month v. Any clinical or laboratory evidence of acute bacterial or viral infection within 2 weeks vi. Patients with an estimated survival time of less than 6 months vii. The following complications exist: systemic autoimmune diseases, active hepatitis (ALT exceeds the normal limit, positive for HBsAg or HCV antibodies), liver failure, severe anemia, cachexia, severe malnutrition, lymphoproliferative diseases, malignant tumors and other underlying diseases that affect immune function. viii. Patients who participate in clinical studies of trial drugs within 28 days, or have randomly visited trial drugs in ongoing clinical studies ix. Pregnant or lactating women x. Any situation considered by the researchers to be unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD4/CD8; | — |
Secondary
| Measure | Time frame |
|---|---|
| Expression of TLR and integrin on neutrophils;Expression of TLR and integrin on atypical pro-inflammatory subsets of monocyte(CD14+CD16++);Expression of NKG2D, NKp44 and CD69 on NK cell subsets;Lymphocyte subsets;TCR Vß repertoire;Twelve cytokines;Neutrophils lymphocytes ratio;Platelets lymphocytes ratio;hsCRP;Homocysteine;Incidence of infection and cardio-cerebrovascular events;Neutrophil MPO level; | — |
Countries
China
Contacts
Public ContactGu Leyi
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed